BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 11255446)

  • 1. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
    Doody RS; Geldmacher DS; Gordon B; Perdomo CA; Pratt RD;
    Arch Neurol; 2001 Mar; 58(3):427-33. PubMed ID: 11255446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
    Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
    Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
    Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
    Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
    Rogers SL; Friedhoff LT
    Eur Neuropsychopharmacol; 1998 Feb; 8(1):67-75. PubMed ID: 9452942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
    Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
    Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
    Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
    Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
    Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
    Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
    Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study.
    Rogers SL; Doody RS; Pratt RD; Ieni JR
    Eur Neuropsychopharmacol; 2000 May; 10(3):195-203. PubMed ID: 10793322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donepezil therapy in clinical practice: a randomized crossover study.
    Greenberg SM; Tennis MK; Brown LB; Gomez-Isla T; Hayden DL; Schoenfeld DA; Walsh KL; Corwin C; Daffner KR; Friedman P; Meadows ME; Sperling RA; Growdon JH
    Arch Neurol; 2000 Jan; 57(1):94-9. PubMed ID: 10634454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
    Salloway S; Ferris S; Kluger A; Goldman R; Griesing T; Kumar D; Richardson S;
    Neurology; 2004 Aug; 63(4):651-7. PubMed ID: 15326237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
    Rogers SL; Friedhoff LT
    Dementia; 1996; 7(6):293-303. PubMed ID: 8915035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
    Harrington C; Sawchak S; Chiang C; Davies J; Donovan C; Saunders AM; Irizarry M; Jeter B; Zvartau-Hind M; van Dyck CH; Gold M
    Curr Alzheimer Res; 2011 Aug; 8(5):592-606. PubMed ID: 21592048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
    Rogers SL
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.